Search Results

You are looking at 71 - 80 of 116 items for :

  • "novel therapy" x
  • All content x
Clear All
Full access

Leigh Gallo, Ronald S. Walters, Jeff Allen, Jenny Ahlstrom, Clay Alspach, Yelak Biru, Alyssa Schatz, Kara Martin, and Robert W. Carlson

novel therapies. However, opportunities for collaboration must begin earlier in the oncology product development process and span multiple agencies to maximize greater effectiveness and access. For example, early communication with other agencies

Full access

Tomas G. Lyons and Mark E. Robson

when to treat these patients; how to sequence these drugs with currently established therapies, particularly platinum agents; how to combine PARPi with other novel therapies; and how to overcome resistance. The hope is that these trials will incorporate

Full access

Olga Frankfurt and Martin S. Tallman

. Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy . Semin Hematol 2002 ; 39 [ suppl 1 ]: 8 – 13 . 114. Lazo G Kantarjian H Estey E . Use of arsenic

Full access

Matthew Mei and George Somlo

. Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma . Leuk Lymphoma 2013 ; 54 : 1658 – 1664 . 13. Fermand JP Katsahian S Divine M . High-dose therapy and autologous blood stem

Full access

Maxim Norkin and John R. Wingard

studying novel therapies . Clin Infect Dis 2010 ; 51 : 1273 – 1280 . 15. Bergeron A Porcher R Sulahian A . The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte

Full access

Matthew P. Banegas, Linda C. Harlan, Bhupinder Mann, and K. Robin Yabroff

-approved agents ( Table 2 ), 7 were approved since 2005. With mounting evidence of improved efficacy for many of these novel therapies (ie, temsirolimus, everolimus, pazopanib), 17 - 19 it will be important to further monitor trends in their use. Figure 1

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dottie A. Shead, and Rashmi Kumar

adjuvant setting. To date, the tailoring of therapy based on poor response to standard preoperative chemotherapy has not yet shown improved outcomes. Preoperative systemic therapy also serves as an excellent research platform to test novel therapies and

Full access

Thomas Melchardt, Katharina Troppan, Lukas Weiss, Clemens Hufnagl, Daniel Neureiter, Wolfgang Tränkenschuh, Konstantin Schlick, Florian Huemer, Alexander Deutsch, Peter Neumeister, Richard Greil, Martin Pichler, and Alexander Egle

and low CRP followed a similar course to that of the low-intermediate group. This may be of clinical importance, because this group with an intermediate risk may include the most patients, who may benefit from more intensive or novel therapy approaches

Full access

Rahul Aggarwal, Tian Zhang, Eric J. Small, and Andrew J. Armstrong

improve on current histopathologic criteria and guide the development of predictive and/or prognostic biomarkers. Current treatment generally entails platinum-based chemotherapy and consideration of clinical trial enrollment; however, novel therapies are

Full access

Jennifer L. Schwartz, Sandra L. Wong, Scott A. McLean, James A. Hayman, Christopher D. Lao, Jeffrey H. Kozlow, Kelly M. Malloy, Carol R. Bradford, Marcus L. Frohm, Douglas R. Fullen, Lori Lowe, and Christopher K. Bichakjian

surgery, radiation therapy, chemotherapy, and novel therapies/clinical trials to individualize patient care. Recommendations regarding long-term clinical monitoring for recurrence in patients with MCC vary among physicians. At UM, physical examinations